18. Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet....
6. Scott LJ. Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma. Drugs. 2017;77(4):435-445. 7. 2022版CSCO淋巴瘤指南 8. Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin ...
CD30 is a transmembrane receptor, selectively expressed on tumor cells of certain lymphatic malignancies, such as Hodgkin's lymphoma, and therefore a privileged target for anti-CD30 antibody-based immunotherapy. However, CD30 is cleaved at the cell surface. Thus, the entire ectodomain (sCD30) ...
The positive rate of CD30 in each subtype of B-cell lymphoma (BCL) was: Typical Hodgkin's lymphoma (cHL) was close to 100%, primarymediastinal (thymus)large B-cell lymphoma (PMBL) >80%, diffuse large B-cell lymphoma-not otherwise specified (DLBcl-NOS) 10%-20%,nodularlymphocytic dominant...
Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin[J]. Blood Res, 2015, 50(4): 254-256. [11] PRINCE H M. CD30 As a target for the treatment of cutaneous T-cell lymphoma[J]. J Clin Oncol, 2015, 33(32): 3691-3696. [12] XU M ...
but also a number of other peripheral T-cell lymphomas—can express this protein. That actually has given us a real opportunity to bring something new to the treatment of patients with peripheral T-cell lymphoma [PTCL], and that’s because the agent, brentuximab vedotin, targets CD30, binds...
Treatment of T-cell non-Hodgkin's lymphoma. virus, human T-cell lymphotropic virus type-1 associated with extranodal NK/T-cell lymphoma nasal type and adult T-cell leukemia/lymphoma, respectively, ... AM Evens,RB Gartenhaus - 《Current Treatment Options in Oncology》 被引量: 264发表: 2004...
Herein, we demonstrate an effective CAR-T cell treatment for recurrent and malignant CD30-positive periphera... Y Wu,D Chen,Y Lu,... - 《Cancer Gene Therapy》 被引量: 0发表: 2021年 Soluble CD30: A Possible Serum Tumor Marker for Primary Effusion Lymphoma CONCLUSION: The serum level of...
Moreover, CD30 is strongly expressed on peripheral T lymphoma cells, the CD30 CART cells tend to target them before targeting mature T cells with weak CD30 expression. Therefore, CAR-T cell therapy targeting CD30 for the treatment of refractory or recurrent CD30-positive PTCL could become a...
作者 CD30阳性淋巴瘤病理专家组 李小秋 CD30-Positive Lymphoma Pathology Expert Group;LI Xiaoqiu 机构地区 复旦大学附属肿瘤医院病理科 出处 《中国癌症杂志》 CAS CSCD 北大核心 2023年第3期228-234,共7页 China Oncology 关键词 淋巴瘤 CD30 免疫组织化学 检测规范 判读标准 Lymphoma CD30 Immunohistochemis...